Oppenheimer Resumes Coverage on BioSante Pharmaceuticals (BPAX) with an Outperform
BPAX Hot Sheet
Rating Summary:1 Buy, 5 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 0
Oppenheimer resumes coverage on BioSante Pharmaceuticals (Nasdaq: BPAX) with an Outperform rating. Price target $6.
To see more analyst ratings on BPAX Click Here.
BioSante Pharmaceuticals, Inc., a biopharmaceutical company, develops products for female sexual health, menopause, contraception, and male hypogonadism.
To see more analyst ratings on BPAX Click Here.
BioSante Pharmaceuticals, Inc., a biopharmaceutical company, develops products for female sexual health, menopause, contraception, and male hypogonadism.
You May Also Be Interested In
- UPDATE: Auriga Starts Akorn (AKRX) at Buy; Unique Product Portfolio with Limited Competition
- UBS Cuts Price Target and Estimates on Analog Devices (ADI); Good Q2, But Slowing Growth in N-T
- Wedbush Starts Erickson Air-Crane (EAC) at Outperform; Aircrane Sales Key to Upside
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
